HemoGenyx Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of a suite of products to address current problems associated with the treatment of blood disorders such as cancers and autoimmune diseases, with bone marrow, or hematopoietic stem cell, transplants, and with viral infections. The firm is engaged in the discovery, development and commercialization of a suite of products to address problems associated with the treatment of blood disorders, such as cancers and autoimmune diseases, and viral infections. Its products include immunotherapy product candidates for the treatment of acute myeloid leukemia (AML) and other blood malignancies and patient conditioning for bone marrow transplantation (the CDX bi-specific antibody and CAR-T therapy), and a cell therapy product for BM/HSC transplantation (the Hu-PHEC). Its lead product, HG-CT-1, is a CAR-T cell therapy designed to treat relapsed or refractory acute myeloid leukemia (R/R AML), which is in a Phase I clinical trial. Its Chimeric Bait Receptor (CBR) is a versatile range of potential treatments based on the methodology of programming immune cells using a type of modifiable synthetic receptor to destroy viral pathogens.
Follow-Up Questions
Hemogenyx Pharmaceuticals PLC의 CEO는 누구입니까?
Dr. Vladislav Sandler은 2017부터 회사에 합류한 Hemogenyx Pharmaceuticals PLC의 Chief Executive Officer입니다.
HOPHF 주식의 가격 성능은 어떻습니까?
HOPHF의 현재 가격은 $0이며, 전 거래일에 decreased 0% 하였습니다.
Hemogenyx Pharmaceuticals PLC의 주요 사업 주제나 업종은 무엇입니까?
Hemogenyx Pharmaceuticals PLC은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
